Arkolith/Insider Trading/XLO/Form 4

Frankenfield Christopher James

Chief Financial OfficerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Nov 25, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
17
0 non-derivative · 17 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 21, 2025Disposed to issuer(D)45K——0
Nov 21, 2025Grant(A)24K——24K
Nov 21, 2025Disposed to issuer(D)24K——0
Nov 21, 2025Grant(A)155K——155K
Nov 21, 2025Disposed to issuer(D)155K——0
Nov 21, 2025Grant(A)925K—$0925K
Nov 21, 2025Grant(A)300K——300K
Nov 21, 2025Disposed to issuer(D)300K——0
Nov 21, 2025Grant(A)150K——150K
Nov 21, 2025Disposed to issuer(D)150K——0
Nov 21, 2025Grant(A)117K——117K
Nov 21, 2025Disposed to issuer(D)117K——0
Nov 21, 2025Grant(A)20K——20K
Nov 21, 2025Disposed to issuer(D)20K——0
Nov 21, 2025Grant(A)45K——45K
Nov 21, 2025Disposed to issuer(D)37K——0
Nov 21, 2025Grant(A)37K——37K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-297204) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML